Sana Biotechnology, Inc. launches an IPO.

IPO of Sana Biotechnology, Inc. (SANA) will take place on February 3, 2021. 

Dana Biotechnology is a developer of a cell engineering platform that will revolutionize therapeutic treatment of oncology, diabetes, central nervous system, cardiovascular diseases and various genetic disorders. The company believes that artificially created cells will be one of the most important transformations in medicine in the few upcoming decades. The long-term strategy for developing a cell engineering platform is to be able to control or modify any gene in the body, replace any damaged or missing cell and noticeably improve access to cellular and gene drugs.

The estimate valuation of the company after its IPO will be US$4.47 billion.

The listed bookrunners of the IPO are Morgan Stanley, Goldman Sachs, JP Morgan and BofA Securities.